Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy

Int J Ophthalmol. 2014 Oct 18;7(5):764-7. doi: 10.3980/j.issn.2222-3959.2014.04. eCollection 2014.

Abstract

Aim: To investigate the role of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) in proliferative diabetic retinopathy (PDR) and to discuss the correlations among t-PA, PAI and vascular endothelial growth factor (VEGF) expressions.

Methods: A total of 36 vitreous samples were collected from 36 patients with PDR (PDR group), and 17 vitreous samples from 17 patients with idiopathic macular hole were used as control. The concentrations of t-PA, PAI and VEGF in samples were determined by ELISA method. The correlations among t-PA, PAI and VEGF expressions were discussed.

Results: The concentrations of t-PA, PAI and VEGF in the PDR group were significantly higher than those in the control group (P<0.001). The t-PA and PAI expressions were highly correlated with the VEGF expression (P<0.001).

Conclusion: In addition to VEGF, a variety of bioactive substances, such as t-PA and PAI, are involved in the pathogenesis involved in the angiogenesis of PDR. VEGF can activate t-PA expression, resulting in collagen tissue degradation and angiogenesis. VEGF may also activate the mechanism for endogenous anti-neovascularization.

Keywords: angiogenesis; plasminogen activator inhibitor; proliferative diabetic retinopathy; tissue plasminogen activator; vascular endothelial growth factor.